Navigation Links
Scientists Uncover New Weapon Against Huntington's
Date:4/3/2009

Treatment could save brain cells from ravages of neurodegenerative disease

FRIDAY, April 3 (HealthDay News) -- Harvard scientists say they've found a possible way to prevent brain cells from falling victim to the ravages of Huntington's disease.

The work is still in the preliminary stages, and the researchers don't know if the strategy will work in humans. Still, a Huntington's disease expert said the findings could lead to a way to combat the incurable condition.

"They suggest a new way that you could approach developing treatments. I think it's going to emerge as a theme," said University of California at Irvine professor Leslie Thompson.

Huntington's disease is inherited, and children of parents with a single faulty gene have at least a 50 percent chance of developing it. The condition typically develops in middle age, causing the body to move involuntarily, leading to symptoms such as balance and coordination problems, slurred speech, swallowing problems and dementia.

Death typically occurs within 10 to 30 years.

There's no treatment to stop the progression of Huntington's disease or cure it, although patients can take drugs to control their symptoms.

"It's like when you have a rotten tooth," said study co-author Dr. Dimitri Krainc. "You can take painkillers so you don't feel the pain, but the tooth is still rotten."

Krainc, an associate professor of neurology at Harvard Medical School, and his colleagues tried to find a way to reduce the build-up of proteins in brain cells stricken by the disease.

Essentially, Krainc said, proteins pile up in the cells and cause problems. "It's like trash that doesn't get picked up in a crowded apartment," he said, "If you don't remove trash, it eventually suffocates you."

Indeed, clogged cells either stop functioning properly or die, Thompson said.

In the new study, the researchers tinkered with the troublesome proteins through genetic modification. They report their findings in the April 3 issue of Cell.

According to Krainc, the researchers found that their approach allowed proteins within the cells to degrade as they're supposed to. The strategy worked in worms, mice and the brain cells taken from dead people.

Drugs known as HDAC inhibitors have the same effect and are already being tested as treatments for Huntington's disease and cancer, Krainc said. The drugs are currently used to treat psychiatric disorders.

There are many unknowns, however. Researchers don't know whether the treatment will work in humans, and the potential costs of drugs are unclear.

Still, research may take a matter of years, not decades, Krainc said.

In the big picture, the new research "could have broad implications for a number of neurodegenerative diseases," Thompson said.

Alzheimer's disease, for example, is also caused when cells become clogged and fail to function properly.

"It's an extremely exciting and promising area of research," Thompson said, "and new and novel."

More information

To learn more about Huntington's disease, try the U.S. National Institutes of Health.



SOURCES: Dimitri Krainc, M.D., Ph.D., professor, neurology, Harvard Medical School, Boston; Leslie Thompson, Ph.D., professor, psychiatry and human behavior, University of California at Irvine; April 3, 2009, Cell


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. New prion protein discovered by Canadian scientists may offer insight into mad cow disease
2. Scientists Probe Sepsis Deadly Secrets
3. Scientists puzzled by severe allergic reaction to cancer drug in the middle Southern US
4. Scientists Develop Natural Protection for Stored Foods
5. Scientists detect presence of marburg virus in african fruit bats
6. Scientists Spot Brains Free Will Center
7. Scientists ID Likely Culprit in Popcorn Lung
8. Scientists explain how insulin secreting cells maintain their glucose sensitivity
9. Scripps Research scientists shed new light on how antibodies fight HIV
10. Scientists, physicians present latest findings in personalized cancer treatment and prevention
11. Scientists demonstate link between genetic variant and effectiveness of smoking cessation meds
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Scientists Uncover New Weapon Against Huntington's
(Date:2/8/2016)... ... , ... According to research by the National Association of ... be certified or obtain continuing education. To increase patient awareness of the lack ... campaign to inform dentists and patients about the possible lack of skills and ...
(Date:2/7/2016)... Texas (PRWEB) , ... February 07, 2016 , ... ... new MyDecision™ program. MyDecision™ empowers employers and organizations with the tools and information ... MyDecision™ combines three elements to cut the cost of providing employee healthcare benefits ...
(Date:2/6/2016)... San Rafael, CA (PRWEB) , ... February 06, 2016 , ... ... 2016 Youth Ultimate Coaching Conference (YUCC) . This event brings together top non-profit leaders, ... is “Gender Equity and Girls Ultimate”. Valerio Iani, Bay Area Disc Program Director of ...
(Date:2/6/2016)... ... February 06, 2016 , ... ... disorder treatment helps to reduce the frequency and level of relapse. ... Re-Establishing Healthy Identity and Purpose,” will explore the critical tasks of the recovery ...
(Date:2/5/2016)... Ontario (PRWEB) , ... February 05, 2016 , ... ... announced the availability of the company's lighter, sleeker next generation LYNX VR Indoor ... plant. , Improvements in design and manufacturing not only reduce the weight ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... 2016 Vestagen Technical Textiles, Inc., a medical ... healthcare and other demanding applications, today announced it has ... replaces Dale Pfost , PhD, who was serving ... also joining Vestagen,s Board of Directors. ® ... barrier technologies that combines fluid repellent, antimicrobial and breathability ...
(Date:2/8/2016)... Ill. , Feb. 8, 2016  Astellas Pharma Inc. ... announced the promotion of James Robinson as president, ... company,s operations in North and South America ... Astellas Pharma US, representing the commercial organization in ... in 2013. Masao Yoshida , who is ...
(Date:2/8/2016)... , Feb. 8, 2016  CTI BioPharma Corp. ... Company received written communication from the U.S. Food and ... FDA has placed a partial clinical hold on the ... Drug ("IND") application for pacritinib. This clinical hold impacts ... the IND and will also affect planned clinical trials. ...
Breaking Medicine Technology: